About Us
Our Company
Founded in 2017 at the Sheba Medical Center, the largest hospital in Israel and recognized among the top 10 in the world by Newsweek in 2019, 2020, 2021, and a teaching hospital of Tel Aviv University. Innovalve’s presence at Sheba’s Heart Center allows for a close collaboration with Sheba’s clinicians, developers and other professionals, along with available access to surgical and interventional cardiology expertise.
Our Leadership
The company is led by experienced managers in the field of biomedical devices and interventional cardiology, and is consulted by an extensive network of global experts, as well as an internationally recognized Scientific Advisory Board.
Founders
PROF. EHUD RAANANI
MD, CO-FOUNDER & CHIEF SCIENTIFIC OFFICER
Prof. Raanani has vast experience in the cardiothoracic field, serves as Director of the Leviev Cardiothoracic
DR. BORIS ORLOV
MD, CO-FOUNDER
Dr. Orlov is a world-wide inventor in the cardiac field, works as a cardiac surgeon and is the Director of
Management
EYAL BAROR
CEO
Eyal has more than 15 years of
experience in managing Hi-Tech
companies and since January 2020…
ORNA LANDAU
Orna has more than 12 years of experience in the medical device and pharmaceutical industry, and 6 years…
GUY SHIMEL
R&D Team leader – Mechanical Engineer (M.Sc.) with 10 years of experience providing effective…
NATALIA KRUGLOV
15 years of professional experience in the field of Medical Devices and R&D Lab, participating in design…
MIRIAM IVENSHITZ
Miriam brings with her more than a
decade of experience in medical
device clinical trial activity, including…
SHAI KARNI
Over 10 years of experience developing cardiovascular medical devices for valve repair and…
YONATAN GREENBERG
DIRECTOR OF OPERATIONS AND ENGINEERING
Our Vision
Our vision is to provide physicians and patients with new non-surgical modalities for safe and effective treatment of heart valve morbidities, in particular – mitral valve regurgitation.
The introduction of novel catheter technologies to replace a defective mitral valve may dramatically alter the existing approach for treating mitral regurgitation. Innovalve’s TMVR System will allow physicians to offer therapy to patients who suffer from mitral regurgitation, and who currently have no good and safe solution/intervention for their condition. Innovalve’s TMVR System has the ability to transform these patients markets from either surgery-based or repair-only options, to include minimally invasive TMVR. Thus, providing clinical benefit comparable to mitral valve replacement surgery, with the lower risks associated with a minimally invasive approach.
